39 patents
Utility
Approach for Treatment of Cancer Via Immunomodulation by Using Talabostat
4 Jan 24
The present invention discloses a method of treating, preventing or ameliorating tumor growth by administering a therapeutic agent that selectively inhibits dipeptidyl peptidase including fibroblast activation protein and dipeptidyl peptidase 8/9 in combination with an immune checkpoint inhibitor.
Luca RASTELLI, Aparna Katoch SAPRA, Vimal MEHTA
Filed: 21 Dec 22
Utility
Prevention or Treatment of Sleep Disorders Using Dexmedetomidine Formulation
28 Dec 23
There is provided a composition suitable for oral transmucosal administration (sublingual) comprising dexmedetomidine.
Harsh NEGI, Deepa SAINI, Sameer SHARMA, Krishnan NANDABALAN, Frank YOCCA
Filed: 5 Sep 23
Utility
Use of sublingual dexmedetomidine for the treatment of agitation
12 Dec 23
The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof.
Krishnan Nandabalan, Frank Yocca, Sameer Sharma, Harsh Negi, Deepa Saini
Filed: 29 Dec 17
Utility
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
7 Dec 23
Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof.
Vasukumar KAKUMANU, David Christian HANLEY, Frank YOCCA, Chetan Dalpatbhai LATHIA, Scott David BARNHART
Filed: 11 Aug 23
Utility
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
30 Nov 23
Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof.
Vasukumar KAKUMANU, David Christian HANLEY, Frank YOCCA, Chetan Dalpatbhai LATHIA, Scott David BARNHART
Filed: 11 Aug 23
Utility
Non-sedating dexmedetomidine treatment regimens
7 Nov 23
Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation.
Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Lavanya Rajachandran, Robert Risinger
Filed: 12 Jan 23
Utility
Film formulations containing dexmedetomidine and methods of producing them
7 Nov 23
Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof.
Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
Filed: 20 Jan 22
Utility
Non-sedating Dexmedetomidine Treatment Regimens
26 Oct 23
Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation.
Vasukumar KAKUMANU, David Christian HANLEY, Frank YOCCA, Chetan Dalpatbhai LATHIA, Lavanya RAJACHANDRAN, Robert RISINGER
Filed: 30 Jun 23
Utility
Treatment Regimen for Cancer Using Immunomodulation
26 Oct 23
The present disclosure provides a regimen for treating a subject afflicted with prostate cancer by administering Talabostat or a pharmaceutically acceptable salt thereof and Pembrolizumab, wherein Talabostat or a pharmaceutically acceptable salt thereof is administered at a dose of about 0.3 mg twice daily on one or more days of a treatment cycle.
Vincent J. O'NEILL
Filed: 5 Feb 21
Utility
Use of sublingual dexmedetomidine for the treatment of agitation
17 Oct 23
The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof.
Krishnan Nandabalan, Frank Yocca, Sameer Sharma, Harsh Negi, Deepa Saini
Filed: 18 Nov 22
Utility
Predictive and Diagnostic Methods for Prostate Cancer
20 Jul 23
The present invention generally relates to a method of diagnosing, prognosing and treating prostate cancer patients.
Krishnan NANDABALAN, Luca RASTELLI
Filed: 20 Jan 23
Utility
Use of Sublingual Dexmedetomidine for the Treatment of Agitation
13 Jul 23
The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof.
Krishnan NANDABALAN, Frank YOCCA, Sameer SHARMA, Harsh NEGI, Deepa SAINI
Filed: 22 Mar 23
Utility
Film Formulations Containing Dexmedetomidine and Methods of Producing Them
4 May 23
Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof.
Vasukumar KAKUMANU, David Christian HANLEY, Frank YOCCA, Chetan Dalpatbhai LATHIA, Scott David BARNHART
Filed: 20 Dec 22
Utility
Non-sedating Dexmedetomidine Treatment Regimens
20 Apr 23
Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation.
Vasukumar KAKUMANU, David Christian HANLEY, Frank YOCCA, Chetan Dalpatbhai LATHIA, Scott David BARNHART, Lavanya RAJACHANDRAN, Robert RISINGER
Filed: 23 Nov 22
Utility
Predictive and diagnostic methods for prostate cancer
28 Mar 23
The present invention generally relates to a method of diagnosing, prognosing and treating prostate cancer patients.
Krishnan Nandabalan, Luca Rastelli
Filed: 9 Jan 18
Utility
Use of Sublingual Dexmedetomidine for the Treatment of Agitation
23 Mar 23
The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof.
Krishnan NANDABALAN, Frank YOCCA, Sameer SHARMA, Harsh NEGI, Deepa SAINI
Filed: 18 Nov 22
Utility
Use of Sublingual Dexmedetomidine for the Treatment of Agitation
16 Mar 23
The present invention discloses a method of treating agitation or the signs of agitation in a subject comprising the sublingual administration of an effective amount of an alpha-2 adrenergic agonist, more particularly Dexmedetomidine, or a pharmaceutically acceptable salt thereof.
Krishnan NANDABALAN, Frank YOCCA, Sameer SHARMA, Harsh NEGI, Deepa SAINI
Filed: 18 Nov 22
Utility
Film formulations containing dexmedetomidine and methods of producing them
24 Jan 23
Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof.
Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
Filed: 24 Nov 20
Utility
Systems and Methods for Detection and Prevention of Emergence of Agitation
15 Dec 22
Disclosed in the present disclosure is a method, system and apparatus for prediction, estimation and prevention of occurrence of agitation episode in a subject predisposed to agitation.
Frank D. YOCCA, Michael DE VIVO, Robert RISINGER, Subhendu SETH, Martin MAJERNIK, Daniel R. KARLIN, Jamileh JEMISON, Alexander WALD, Miguel AMÁVEL DOS SANTOS PINHEIRO
Filed: 11 Aug 22
Utility
Film formulations containing dexmedetomidine and methods of producing them
6 Dec 22
Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof.
Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
Filed: 23 Dec 21